Pfizer sued Teva in the District Court of Delaware for the Infringement of US 5273995 ("[R-(R*R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof," issued December 28, 1993) based on Teva's filing of an ANDA to manufacture a generic version of Pfizer's Lipitor® (Atorvastatin hemicalcium). This is second time Pfizer has sued Teva for the same patent for different strength. The CAFC on complaint from Ranbaxy has invalidated the claim 6 of this patent. Pfizer is trying to reissue the said patent and USPTO has twice rejected Pfizer request as reported earlier by this blog
Monday, 5 May 2008
Drug companies oppose bid to link marketing, patents
The drug controller general of India (DCGI), Surinder Singh, had said in a conference last week that he intended to reject applications to sell copycat versions of a patented drug from other drug makers in India. This could avoid ticklish situations where a generics manufacturer gets the marketing go-ahead from DCGI for a drug patented by another. (link to full text article)
Subscribe to:
Posts (Atom)
